The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects.
about
Preclinical evidence of rapid-onset antidepressant-like effect in Radix Polygalae extractThe molecular neurobiology of depressionKetamine, sleep, and depression: current status and new questionsTargeting the glutamatergic system to treat major depressive disorder: rationale and progress to dateChronic treatment with mood-stabilizers attenuates abnormal hyperlocomotion of GluA1-subunit deficient miceGlycine transport inhibitors for the treatment of schizophreniaForebrain glutamatergic neurons mediate leptin action on depression-like behaviors and synaptic depressionKetamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT): a multicentre, double-blind, randomised, parallel-group, superiority trialEffects of nicotine on depressive-like behavior and hippocampal volume of female WKY rats.Is there a role for glutamate-mediated excitotoxicity in inflammation-induced depression?Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.Memantine: a review of possible uses in child and adolescent psychiatryPremorbid risk factors for major depressive disorder: are they associated with early onset and recurrent course?The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia.Phosphodiesterase 4 inhibitors enhance sexual pleasure-seeking activity in rodents.NMDA receptor antagonists augment antidepressant-like effects of lithium in the mouse forced swimming test.Ketamine and the next generation of antidepressants with a rapid onset of actionRoles of p75(NTR), long-term depression, and cholinergic transmission in anxiety and acute stress copingImpact of subanesthetic doses of ketamine on AMPA-mediated responses in rats: An in vivo electrophysiological study on monoaminergic and glutamatergic neurons.AMPA Receptor-mTOR Activation is Required for the Antidepressant-Like Effects of Sarcosine during the Forced Swim Test in Rats: Insertion of AMPA Receptor may Play a Role.Study protocol for the randomised controlled trial: Ketamine augmentation of ECT to improve outcomes in depression (Ketamine-ECT study).Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled studyExpression of monoamine transporters, nitric oxide synthase 3, and neurotrophin genes in antidepressant-stimulated astrocytesAntidepressant-like cognitive and behavioral effects of acute ketamine administration associated with plasticity in the ventral hippocampus to medial prefrontal cortex pathway.Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorderMulti-locus genome-wide association analysis supports the role of glutamatergic synaptic transmission in the etiology of major depressive disorder.Higher DHEA-S (dehydroepiandrosterone sulfate) levels are associated with depressive symptoms during the menopausal transition: results from the PENN Ovarian Aging StudyNMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice.Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine.The Emerging Role of Metabotropic Glutamate Receptors in the Pathophysiology of Chronic Stress-Related DisordersAssessing the neuronal serotonergic target-based antidepressant stratagem: impact of in vivo interaction studies and knockout modelsNMDA Receptor Antagonists for Treatment of DepressionIntracellular- and extracellular-derived Ca(2+) influence phospholipase A(2)-mediated fatty acid release from brain phospholipids.Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant propertiesHINT1 protein cooperates with cannabinoid 1 receptor to negatively regulate glutamate NMDA receptor activity.The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of mania.Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potentialA 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression.
P2860
Q21132322-02855605-468E-4478-A506-A020029261F1Q24656261-AF1BBB9C-CA88-4820-AB06-D923A1F2E449Q26828564-7B4CDBEF-3C4B-42F9-8EED-79B6CE611389Q27004490-D1214D1D-009C-496E-8EC7-5D9B0526FFBBQ28539744-D9B8D096-ED3B-4CA0-BDC4-602DC4528BE0Q30477522-FE46A713-9124-432B-AC94-5449F74ACDFDQ30508512-2FE3D169-D96B-4D42-A85B-D23ED1B61A6DQ33607667-E684AF59-07DB-4D9A-A242-EE8DB3094DEDQ33624583-C72D1D18-B788-480D-B5F8-831CA83FEEAEQ34051382-07B99397-AB5F-45F4-9F70-A3F4866FACB4Q34330678-0E2C6819-3CFE-4EC0-B675-51D009BDE9A4Q34344303-4FC7B00F-304A-498A-B2B3-F5DC1947262DQ34574186-3758E935-0959-42A0-9EA1-9EA48842E573Q34659000-0DA09E52-3C33-4C31-9728-3778F5B85F24Q34728708-BA7FB1A6-98EC-4817-8B9C-7128DB6408CDQ34974649-3F3F8CCF-F115-4438-9C15-91A57FCF53C2Q34978041-99E90E2E-FF1E-4B98-B614-CB79C752F361Q35592894-78B06996-56DE-48A9-BE95-94AD218B28E8Q35748576-58B894BA-EFC0-4BE3-B849-D71BFA4E5BC5Q35753372-32E29D10-DF81-427A-8BED-34B2DA9E452FQ35816486-60A58664-4293-4617-9CA5-7668F1798C77Q35892768-FEDA8700-C860-48A1-BF78-8804AFDD8A97Q35899423-FCEEA6DB-DD33-4482-98D8-D26C78B4F171Q35952277-BBC6ACC0-C788-4E4B-ABF7-75B4B1277F80Q36434538-2BB55A53-2DFD-4D21-946E-EF530224ABDBQ36591241-4DDBF2ED-1C06-4D51-A5E5-D4A418B12B11Q36950127-FB36CE37-F6D9-4B6F-94BF-089BD5BC1DAFQ37030206-B31E4956-4A31-4A00-81B8-29E6A9240D68Q37099118-AFEF4FEB-B44E-4850-84FC-760470A2EA6FQ37172873-20C03443-E30C-4414-BEE4-0B006C5A7ACDQ37206280-C5F1CE79-15D2-44C7-A8D3-0559C8A8748EQ37277388-4269E46A-3EF5-4C47-A6EA-78B4EBEA9E53Q37328073-CB087343-F3F3-438B-9C6E-0E0E5773E02FQ37330681-A62E8083-ADCF-41F1-8334-A10BD7C28946Q37364657-95A1A3B4-EB69-4BD0-93DA-2D2EAE8A38BAQ37387700-6A33682C-CCF4-4A0E-AD79-AAC75E1E373AQ37442874-2DE1AF43-7677-4BE9-8C96-89F27515E0DBQ37461666-1CC946C6-4671-4F35-A54E-F09C418410BFQ37548763-256B741A-F9C9-44B3-832C-096724B05EF0Q37639101-064D9E6D-FD57-4898-B569-9C7E5FE0BB26
P2860
The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The role of glutamate in mood ...... ng its antidepressant effects.
@en
The role of glutamate in mood ...... ng its antidepressant effects.
@nl
type
label
The role of glutamate in mood ...... ng its antidepressant effects.
@en
The role of glutamate in mood ...... ng its antidepressant effects.
@nl
prefLabel
The role of glutamate in mood ...... ng its antidepressant effects.
@en
The role of glutamate in mood ...... ng its antidepressant effects.
@nl
P2860
P1476
The role of glutamate in mood ...... ng its antidepressant effects.
@en
P2093
Carlos A Zarate
Sungho Maeng
P2860
P2888
P304
P356
10.1007/S11920-007-0063-1
P407
P577
2007-12-01T00:00:00Z